Varian Medical Systems led the robotic-assisted ultrasound device developer's series C round, which also included Johnson & Johnson Innovation - JJDC.
HistoSonics, the US-headquartered developer of a soundwave-based medical treatment device, completed a $54m series C round yesterday that was led by cancer treatment technology provider Varian Medical Systems.
Johnson & Johnson Innovation – JJDC, the corporate venturing arm of medical group Johnson & Johnson, also took part in the round, as did venture capital firm Lumira Ventures, investment firm Venture Investors, State of Wisconsin Investment Board and private investor Fred Moll.
HistoSonics is developing an autonomous robotics platform that will…
